Literature DB >> 20652210

[Therapeutic strategies in acute decompensated heart failure and cardiogenic shock].

M Buerke1, H Lemm, M Russ, A Schlitt, K Werdan.   

Abstract

As the population of elderly people is increasing, the number of patients requiring hospitalization for acute exacerbations is rising. Traditionally, these episodes of hemodynamic instability were viewed as a transient event characterized by systolic dysfunction, low cardiac output, and fluid overload. Diuretics, along with vasodilator and inotropic therapy, eventually became elements of standard care. In a multicenter observational registry (ADHERE--Acute Decompensated Heart Failure National Registry) of more than 275 hospitals, patients with acute decompensated heart failure were analyzed for their characteristics and treatments options. These data have shown that this population consists of multiple types of heart failure, various forms of acute decompensation, combinations of comorbidities, and varying degrees of disease severity. The challenges in the treatment require multidisciplinary approaches since patients typically are elderly and have complex combinations of comorbidities. So far only a limited number of drugs is currently available to treat the different groups. Over the past years it was shown that even "standard drugs" might be deleterious by induction of myocardial injury, worsening of renal function or increasing mortality upon treatment. Therefore, based on pathophysiology, different types of acute decompensated heart failure require specialized treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652210     DOI: 10.1007/s00108-009-2537-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  48 in total

1.  Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes.

Authors:  Olga Milo; Gad Cotter; Edo Kaluski; Alex Brill; Alex Blatt; Ricardo Krakover; Zvi Vered; Rami Hershkoviz
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

2.  Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.

Authors:  Maria Rosa Costanzo; Mitchell Saltzberg; Jeanne O'Sullivan; Paul Sobotka
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

3.  BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.

Authors:  Stephen S Gottlieb; D Craig Brater; Ignatius Thomas; Edward Havranek; Robert Bourge; Steven Goldman; Farere Dyer; Miguel Gomez; Donald Bennett; Barry Ticho; Evan Beckman; William T Abraham
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

4.  Predictors of readmission among elderly survivors of admission with heart failure.

Authors:  H M Krumholz; Y T Chen; Y Wang; V Vaccarino; M J Radford; R I Horwitz
Journal:  Am Heart J       Date:  2000-01       Impact factor: 4.749

5.  The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF).

Authors:  Mihai Gheorghiade; Wendy Gattis Stough; Kirkwood F Adams; Allan S Jaffe; Victor Hasselblad; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2005-09-19       Impact factor: 2.778

6.  The pathogenesis of acute pulmonary edema associated with hypertension.

Authors:  S K Gandhi; J C Powers; A M Nomeir; K Fowle; D W Kitzman; K M Rankin; W C Little
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

7.  Comparison of dopamine and norepinephrine in the treatment of shock.

Authors:  Daniel De Backer; Patrick Biston; Jacques Devriendt; Christian Madl; Didier Chochrad; Cesar Aldecoa; Alexandre Brasseur; Pierre Defrance; Philippe Gottignies; Jean-Louis Vincent
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

8.  Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.

Authors:  R D Anderson; E M Ohman; D R Holmes; I Col; A L Stebbins; E R Bates; R J Stomel; C B Granger; E J Topol; R M Califf
Journal:  J Am Coll Cardiol       Date:  1997-09       Impact factor: 24.094

9.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Authors:  J S Hochman; L A Sleeper; J G Webb; T A Sanborn; H D White; J D Talley; C E Buller; A K Jacobs; J N Slater; J Col; S M McKinlay; T H LeJemtel
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

10.  Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.

Authors:  Martin A Russ; Roland Prondzinsky; Arnd Christoph; Axel Schlitt; Ute Buerke; Gerold Söffker; Henning Lemm; Michael Swyter; Nikolas Wegener; Matthias Winkler; Justin M Carter; Sebastian Reith; Karl Werdan; Michael Buerke
Journal:  Crit Care Med       Date:  2007-12       Impact factor: 7.598

View more
  1 in total

Review 1.  [Acute heart failure].

Authors:  U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-06-13       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.